Holen Sie sich die Stockscreener-App
6.01
1.15%
-0.07
Handel nachbörslich:
6.01
Schlusskurs vom Vortag:
$6.08
Offen:
$6.08
24-Stunden-Volumen:
540.86K
Relative Volume:
0.51
Marktkapitalisierung:
$248.79M
Einnahmen:
$134.48M
Nettoeinkommen (Verlust:
$-38.94M
KGV:
-6.3038
EPS:
-0.9534
Netto-Cashflow:
$-19.34M
1W Leistung:
+15.80%
1M Leistung:
+24.69%
6M Leistung:
-30.84%
1J Leistung:
-22.75%
1-Tages-Spanne:
$5.86
$6.115
1-Wochen-Bereich:
$5.25
$6.225
52-Wochen-Spanne:
$4.48
$13.22
Rxsight Inc Stock (RXST) Company Profile
Firmenname
Rxsight Inc
Sektor
Branche
Telefon
949-521-7822
Adresse
100 COLUMBIA STREET, ALISO VIEJO
Compare RXST vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
6.01 | 233.48M | 134.48M | -38.94M | -19.34M | -0.9534 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Eingeleitet | William Blair | Mkt Perform |
| 2025-07-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-07-10 | Herabstufung | Jefferies | Buy → Hold |
| 2025-07-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-07-09 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | Eingeleitet | Piper Sandler | Neutral |
| 2025-04-09 | Herabstufung | UBS | Buy → Neutral |
| 2025-04-04 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2025-04-03 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-12-20 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-10-29 | Eingeleitet | Jefferies | Buy |
| 2024-08-20 | Bestätigt | Needham | Buy |
| 2024-08-06 | Bestätigt | Needham | Buy |
| 2024-05-07 | Bestätigt | BTIG Research | Buy |
| 2023-12-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
Alle ansehen
Rxsight Inc Aktie (RXST) Neueste Nachrichten
UBS Adjusts Price Target on RxSight to $5.50 From $9, Maintains Neutral Rating - marketscreener.com
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer - hrtoday.in
Midday Stock Roundup: Rivian Automotive Up on Piper Sandler Upgrade - Orange County Business Journal
Rxsight Inc (RXST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rxsight Inc (RXST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Leadership watch: RxSight, Exonate tap new CEOs; CooperVision, Lumenis, and OSU fill top roles - Glance by Eyes On Eyecare
Rxsight Inc (RXST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rxsight Inc (RXST) Valuation: PE, PB & Fair Value Analysis - TradingKey
RxSight grants new CEO Aziz Mottiwala stock options for 571,286 shares at $5.19 each - Bitget
RxSight grants inducement stock options and RSU... - Pluang
New RxSight CEO's 2.31M RSU award vests over three years - Stock Titan
Rxsight Inc (RXST) Income Statement - TradingKey
Levi & Korsinsky Notifies RxSight, Inc. (RXST) Shareholders of Class Action Lawsuit and September 22, 2025 Deadline - The National Law Review
RxSight (RXST) Stock Fair Value Falls After Soft Q2 Trends And Guidance Cut - Yahoo Finance
Rxsight Inc (RXST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Rxsight Inc (RXST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Form 4 Rxsight Inc For: 24 July By Investing.com - Investing.com Nigeria
RxSight, Inc. (RXST) awards CEO 2,312,138 RSUs and 571,286 options - Stock Titan
Lost Money on RxSight, Inc. (RXST)? Urged to Join Class Action Before September 22, 2025Contact Levi & Korsinsky - The National Law Review
RXST|Rxsight Inc|Price:5.205|Chg%:-0.165 - TradingKey
Rxsight Inc (RXST) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
RxSight, Inc. (RXST) Stock Analysis: Can this Medical Device Innovator Surge with a 56.96% Potential Upside? - DirectorsTalk Interviews
Rxsight Inc (RXST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RXST|Rxsight Inc|Price:5.155|Chg%:-0.215 - TradingKey
(RXST) Movement as an Input in Quant Signal Sets - Stock Traders Daily
RxSight Lands Tarsus Commercial Leader as CEO - Orange County Business Journal
RxSight (RXST) surges 6.1%: Is this an indication of further gains? - MSN
RxSight appoints new CEO - MSN
RXST stock holds as RxSight advances its light-adjustable lens business - Ad-hoc-news.de
BlackRock Portfolio Management (RXST) discloses 7.2% beneficial stake in RxSight - Stock Titan
BTIG Maintains RxSight(RXST.US) With Hold Rating, Announces Target Price $5.25 - Moomoo
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO) - The Globe and Mail
RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance
BTIG Maintains RxSight(RXST.US) With Hold Rating, Maintains Target Price $5.25 - Moomoo
RXST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
RxSight Tags Aziz Mottiwala as President and CEO, Ron Kurtz, MD, as CMO - VisionMonday.com
RxSight names Aziz Mottiwala as new CEO effective July 20 - Investing.com UK
RxSight names Aziz Mottiwala as new CEO effective July 20 By Investing.com - Investing.com Australia
RxSIGHT announces significant leadership appointments - Bitget
Ron Kurtz Steps Down as RxSight CEO - Orange County Business Journal
RxSight Names Aziz Mottiwala as CEO - Moomoo
RxSight (NASDAQ: RXST) hires new CEO, sets $14M equity package - Stock Titan
RxSight Announces Appointments of Aziz Mottiwala as Chief - GlobeNewswire
Alcon & RxSight Collaborate to Develop Adjustable PCIOL Technology - Zacks Investment Research
Alcon collaborates with RxSight to develop adjustable PCIOLs - MSN
Alcon, RxSight announce collaboration to develop adjustable presbyopia-correcting IOLs - Ophthalmology Times Europe
RxSight Q2 sales sink 20% as Alcon deal bolsters 2026 outlook - MSN
RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook - TradingView
RxSight (RXST) Faces Investigation Over Board's Fiduciary Duties - GuruFocus
Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors - The AI Journal
Finanzdaten der Rxsight Inc-Aktie (RXST)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rxsight Inc-Aktie (RXST) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Goldshleger Ilya | See remarks |
Sep 25 '25 |
Option Exercise |
4.27 |
23,445 |
99,998 |
65,691 |
1.04%
11.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):